72 results about "Anti platelet" patented technology

Aspects of the application provide anti-hemojuvelin antibodies and methods of using the same in treating myelofibrosis and / or conditions associated with myelofibrosis.

In some embodiments provided herein is a method of treating a coagulopathy in a subject, the method including administering to the subject in need thereof an effective amount of a composition including platelets or platelet derivatives and an incubating agent including one or more salts, a buffer, optionally a cryoprotectant, and optionally an organic solvent, wherein the subject has been treated or is being treated with an antiplatelet agent.

The invention discloses application of compound resina draconis in preparation of a medicine for treating acute myocardial infarction. The compound resina draconis has the effects of resisting free radical oxidation and platelet aggregation, expanding coronary artery, inhibiting increase of myocardial enzymology CPK and LDH and reducing myocardial oxygen consumption, so that the myocardial infarction range is reduced, and myocardial ischemic ST segment elevation is improved; the compound is combined with aspirin for treating acute myocardial infarction, and the compound and aspirin have a synergistic effect, play a role in resisting platelet aggregation and inhibit synthesis of thromboxane A2, and show a good ischemic myocardial protection effect. Meanwhile, according to the technical scheme that the compound resina draconis is used independently or combined with aspirin, the application range of the medicine is widened, contribution is made for research and development of the medicine for relieving side effects caused by aspirin treatment, and the application prospect is good.

Described herein are methods and kits for the detection of platelet-activating pathogenic antibodies in samples from patients suspected of having platelet-activating antibodies or non-HIT anti-PF4 antibody mediated syndromes using platelets and polyvinyl sulfonate or salts thereof. Upon platelet activation, thrombospondin-1 (TSP1), a platelet granule protein, is released and can be detected using a TSP1 antigen capture enzyme linked immunosorbent assay (ELISA) to accurately measure platelet activation.

Aminopyrimidine containing compounds that inhibit both Mer tyrosine kinase (MerTK) activity and Tyro3 kinase activity are disclosed herein. Additionally disclosed are methods of synthesis and use of the aminopyrimidine containing compounds as anti-cancer agents, immunostimulatory and immunomodulatory agents, anti-platelet agents, anti-infective agents, and as adjunctive agents.

This invention relates to the fields of molecular biology and biomedicine, disclosing plasma-active peptides with antithrombotic effects and their uses. The invention obtains various active peptides from plasma through screening and solid-phase synthesis, and confirms their biological activity through in vitro platelet aggregation experiments and in vivo arterial thrombosis model experiments. Results show that peptides 1957, 1960, and 1961 significantly inhibit collagen-induced platelet aggregation, exhibiting good antiplatelet activity; animal experiments show that peptides 1955, 1957, 1960, and 1961 significantly inhibit arterial thrombosis. These active peptides are derived from endogenous plasma components, belonging to natural antithrombotic substances, possessing good physiological compatibility and safety advantages, and reducing the risk of immunogenicity and adverse reactions. These peptides can exert antithrombotic effects without relying on traditional antiplatelet drugs, providing a new source of active molecules and treatment options for the prevention and treatment of thrombotic diseases.

The application belongs to the technical field of pharmaceutical preparations, and specifically provides a kind of indobufen freeze-dried oral disintegrating tablet and a preparation method thereof.The freeze-dried oral disintegrating tablet contains indobufen and xanthan gum, and the freeze-dried oral disintegrating tablet can be obtained by freeze-drying technology after the above components are prepared into a suspension.The freeze-dried oral disintegrating tablet provided by the application has the technical characteristics of good properties, complete demolding, high drug loading, good content uniformity, rapid disintegration and rapid dissolution, and can meet the needs of rapid anti-platelet therapy in acute thrombosis events.

The present application relates to the technical field of in vitro detection, and particularly relates to a platelet aggregation function detection reagent and application thereof.The platelet aggregation function detection reagent provided by the present application comprises a fibrin activator and an ADP reagent, the fibrin activator adopts a novel high-purity porcine dermal collagen polypeptide component Prionex, and the combination with glycine significantly improves the stability of the fibrin activator, the platelet inhibitor tirofiban is used in combination with PEG6000, the accuracy of the detection result is improved, and the sensitivity to the anti-platelet aggregation drug is improved; the ADP reagent adopts chitosan, the activity and stability are improved, and the ADP reagent can be widely applied to clinical diagnosis of platelet aggregation function.

The invention belongs to the technical field of medicines, and discloses application of pantethine in preparation of medicines for preventing and / or treating thrombotic diseases or medicines for inhibiting platelet activation or regulating vascular endothelial cell functions. In-vivo and in-vitro experiments prove that pantethine can remarkably relieve thrombus load in a mouse thrombus model, down-regulate expression of vWF (von Willebrand Factor), up-regulate expression of TFPI (Tissue Factor Path Inhibitor) and TH BD (Thromboregulatory Protein), and antagonize platelet adhesion, aggregation and activation induced by a platelet activator. The action mechanism is closely related to inhibition of reactive oxygen species (ROS) generation and NF-kappa B signal channel activation, and improvement of endothelial cell functions. It can be known from the invention that pantethine plays an antithrombotic role from multiple aspects, and is suitable for preparation of antithrombotic drugs for prevention or treatment. The invention provides a new drug choice for prevention and treatment of thrombotic diseases.

The application belongs to the technical field of biotechnology, and particularly relates to a kind of snake venom polypeptide and application thereof.The snake venom polypeptide is polypeptide DACU-1, polypeptide DACU-2 or polypeptide DACU-3.The application provides a kind of new snake venom polypeptide, including three polypeptides, and the three polypeptides all have anti-platelet aggregation activity, and have the activity of inhibiting platelet aggregation under the stimulation of ADP, arachidonic acid, collagen, thrombin and other various activators, and have the potential to be developed into anti-platelet drugs, functional foods and health products.

The application discloses a preparation method and application of a paeonol derivative, and relates to the technical field of biomedicine. The paeonol derivative has the chemical structure as shown in the following formula: or. The paeonol extraction preparation method is simple, and the extraction rate of the paeonol is high. The prepared paeonol derivative has more excellent antioxidant activity, and the anti-inflammatory effect is enhanced, the anti-platelet aggregation effect is better, and the paeonol derivative also has good inhibitory activity on the occurrence and development of diabetic retinopathy.

The invention relates to the technical field of medicinal chemistry, in particular to a novel carbamate fumarate, and a crystal form, an amorphous form and a preparation method thereof. The carbamate fumarate and the crystal form and the amorphous form thereof have high stability and solubility and low hygroscopicity, the medicinal performance is improved, the platelet aggregation resisting effect is better, the medicine effect is higher, and clinical application of the medicine is facilitated.

The invention relates to the technical field of medicines, in particular to application of benzbromarone in preparation of antithrombotic drugs. The research finds that benzbromarone clinically used for treating hyperuricemia can be combined with HSP47 on platelets to inhibit the interaction between the HSP47 and collagen so as to reduce platelet activation and thrombosis, which prompts that benzbromarone is an HSP47 inhibitor with an anti-platelet effect; benzbromarone has the effects of inhibiting mouse common carotid artery thrombosis and relieving cerebral ischemia reperfusion injury. Experiments finally confirm that benzbromarone can inhibit formation of common carotid artery thrombosis, does not affect the blood coagulation function, is low in cytotoxicity, has the drug effect similar to that of aspirin and clopidogrel which are commonly used at present, and can become an effective and safe therapeutic drug for cerebral arterial thrombosis.

The application includes a description of anti-hemojuvelin antibodies and methods for their use in the treatment of myelofibrosis and / or myelofibrosis-related conditions.

Provided herein are devices, systems, methods, and compositions, including compositions for coupling to a surface of an implantable article, the compositions comprising an anticoagulant comprising a direct factor Xa inhibitor and at least one of (a) an antiplatelet drug, (b) an anticoagulant comprising a direct factor IIa inhibitor, and (c) an anti-inflammatory drug comprising colchicine.

The present disclosure provides methods for determining whether a subject has platelet hyperreactivity. Further provided are methods for determining risk of developing a platelet-mediated cardiovascular and / or limb event in a subject, as well as determining whether a subject has a condition associated with platelet hyperreactivity. Still further provided are methods for preventing a cardiovascular and / or limb event in a subject in need thereof; treating or preventing a condition associated with platelet hyperreactivity in a subject in need thereof; and, monitoring the progression of a condition associated with platelet hyperreactivity in a subject diagnosed with the condition. Methods for determining the effect of an antiplatelet treatment on development of a condition associated with platelet hyperreactivity in a subject diagnosed with the condition, and identifying an antiplatelet treatment useful for slowing down the progression or treating a condition associated with platelet hyperreactivity in a subject diagnosed with the condition are also provided.

The invention provides an isoquinoline derivative with a novel structure, a pharmaceutically acceptable salt thereof, a preparation method of the isoquinoline derivative, a pharmaceutical composition containing the isoquinoline derivative and pharmaceutical application of the isoquinoline derivative, and belongs to the technical field of medicines. In-vitro experiments show that the isoquinoline derivative has significant inhibitory activity on arachidonic acid-induced platelet aggregation, and the antiplatelet activity of part of compounds is superior to that of aspirin. In a rat carotid artery thrombosis model induced by FeCl3, the isoquinoline derivative remarkably prolongs thrombosis time and reduces thrombus weight, and the in-vivo antithrombotic curative effect of the isoquinoline derivative is equivalent to that of aspirin and ticagrelor. A mouse tail bleeding model shows that the side effects of bleeding amount and bleeding time of the isoquinoline derivative are obviously lower than those of aspirin and ticagrelor. Therefore, the series of isoquinoline derivatives have the advantages of efficient antithrombotic effect and low bleeding risk, and have good application prospects in preparation of drugs for preventing and treating thrombotic diseases. In addition, the preparation method provided by the invention has the advantages of easily available raw materials, simple steps and strong operability, and the obtained target product has high quality and good efficiency.

The embodiments herein provide hemostatic compositions, methods, and kits comprising composite polymer particles. Upon contact with blood or other physiological fluids, the composite particles adsorb fluid and aggregate into a shape-retentive mass that halts bleeding. In certain embodiments, the particles comprise polymers of 2-hydroxyethyl methacrylate, 2-hydroxypropyl methacrylate, or combinations thereof. The particles may be used alone or blended with additional hemostatic agents. Methods of inducing hemostasis are provided for diffuse oozing, or surgical, mucosal, organ surface, fragile tissue or traumatic bleeding, including in patients receiving anticoagulant or antiplatelet therapy. Kits comprising sterile packages of composite particles, optionally with applicators, substrates, or sprays, are disclosed. The compositions exhibit intrinsic hemostatic activity and synergistically enhance the performance of conventional hemostats, achieving rapid clotting. After hemostasis is achieved, the compositions remain in situ as a conforming protective layer, reducing the need for additional covering materials and decreasing risk of re-bleeding.

The application discloses a method for improving blood compatibility of PMP hollow fiber membranes for ECMO by using zwitterionic-nano silver antifouling and antibacterial coating, and the steps of the preparation method are as follows: (1) dissolving zwitterionic polymers and dopamine hydrochloride with different concentrations in PBS; (2) after cleaning the PMP membrane, the PMP membrane is soaked in the modified liquid obtained in step (1), so that the zwitterionic polymers are adhered to the membrane; (3) the above PMP hollow fiber membrane is sequentially immersed in AgNO3 solution, deionized water and NaBH4 solution, so that Ag + is fixed on the membrane surface, and silver nanoparticles are formed in situ on the membrane surface. Experiments prove that the method for improving blood compatibility of PMP hollow fiber membranes for ECMO by using zwitterionic-nano silver coating is simple and has strong universality, and the prepared PMP hollow fiber membrane has high hydrophilicity, excellent anti-platelet adsorption, anti-platelet adsorption and anti-protein adhesion performance, is beneficial to inhibiting thrombosis, and has good blood compatibility and biocompatibility.

Disclosed is a method for evaluation of residual platelet thrombotic potential in a patientundergoing antiplatelet therapy with acetylsalicylic acid which comprises determination ofplatelet tissue factor (TF) expression in a patient's blood sample.

Disclosed in the present invention is the use of an extracellular vesicle as a marker for immune thrombocytopenia. The extracellular vesicle (EV) is derived from platelets, and the extracellular vesicle is secreted by an anti-platelet membrane glycoprotein autoantibody by means of activating the AKT pathway. On the basis of the use, provided is a detection kit for diagnosing immune thrombocytopenia, wherein the detection kit can be used for detecting extracellular vesicles.

The present application provides a kind of nereid polypeptide antithrombotic preparation, belong to the technical field of biopharmaceuticals.The present application finds that nereid plasmin polypeptide can inhibit the reaction of thrombin and fibrinogen to generate fibrin, thereby inhibiting the blood clotting reaction through in vitro test.Nereid plasmin polypeptide is determined for in vitro anti-platelet aggregation activity, and the inhibition rate of 640 μg / ml nereid plasmin polypeptide for anti-platelet aggregation is 75.68%, close to the inhibition effect of 1 mg / ml aspirin.The present application finds that nereid plasmin polypeptide group has the pharmacodynamic effect of reducing the weight of thrombus and the ratio of thrombus weight and length through nereid plasmin polypeptide antithrombotic effect test, has good antithrombotic effect, and can be used as nereid polypeptide antithrombotic preparation.

The invention belongs to the field of medicinal chemistry, and particularly relates to ligustrazine stilbene polyphenol aromatic acid ether compounds, pharmaceutically acceptable salts thereof, a preparation method thereof, a pharmaceutical composition and an application of the ligustrazine stilbene polyphenol aromatic acid ether compounds. The ligustrazine stilbene polyphenol aromatic acid ether compound and the pharmaceutically acceptable salt thereof have a remarkable anti-platelet aggregation effect, and can be used for preparing drugs for resisting platelet aggregation, preventing or treating cardiovascular diseases or treating or preventing thromboembolic diseases.

The invention belongs to the technical field of pharmaceutical preparations, and particularly provides an indobufen oral soluble film and a preparation method thereof. The oral soluble film contains indobufen, a film-forming material and a plasticizer, and after the components are prepared into a suspension, the oral soluble film can be obtained through coating and drying. The oral soluble film provided by the invention has the technical characteristics of complete appearance, good mechanical properties, high drug loading capacity, rapid disintegration, rapid dissolution, no bitter taste and good mouthfeel, and can meet the requirements of rapid antiplatelet treatment in acute thrombosis events.

The present invention discloses a compound of any of the general formulas (la) to (Ig): pharmaceutical compositions comprising said compounds and their use in the treatment of diseases, especially a disease is mediated by ACKR3, preferably a cardiovascular disease or a platelet disorder. In addition, method for treating a disease in which mediation, such as inhibition, regulation and / or modulation, of ACKR3 is beneficial in a human or a warm-blooded or mammal animal in need of such treatment is disclosed.

Aspects of the application provide anti-hemojuvelin antibodies and methods of using the same in treating myelofibrosis and / or conditions associated with myelofibrosis.

This invention relates to an intravascular blood flow guiding device with an endothelialization-promoting coating. After the coating is applied to the surface of the blood flow guiding device, it can regulate the biological functions of circulating endothelial progenitor cells within the blood vessel, including promoting oriented extracellular matrix formation, promoting cell-extracellular matrix adhesion, and promoting endothelial cell proliferation and maturation. This results in: enhanced adhesion, proliferation, and migration capabilities of endothelial progenitor cells; significantly improved acceleration of the endothelialization process; excellent anti-platelet and anti-SMC adhesion properties; and, combined with the hemodynamic optimization effect of the blood flow guiding device, accelerated functional remodeling of the tumor-bearing artery.

Disclosed in the present invention is the use of an extracellular vesicle as a marker for immune thrombocytopenia. The extracellular vesicle (EV) is derived from platelets, and the extracellular vesicle is secreted by an anti-platelet membrane glycoprotein autoantibody by means of activating the AKT pathway. On the basis of the use, provided is a detection kit for diagnosing immune thrombocytopenia, wherein the detection kit can be used for detecting extracellular vesicles.

The present application relates to a kind of anti-platelet aggregation drugs and its use.The drug is the compound of structure I, or its pharmaceutically acceptable salt, solvate or deuteride;The compound of the present application has significant anti-platelet aggregation effect, more suitable water solubility and good stability, and is expected to become a new type of injectable anti-platelet aggregation drug.

The invention relates to an application of a patent medicine Tenapanor approved by FDA in preparing a medicament for resisting platelet and arterial thrombosis. The medicament can be used for effectively inhibiting platelet activation and aggregation and arterial thrombosis block formation. The invention relates to an FDA approved patent medicine Tanipanol capable of effectively inhibiting platelet activation and aggregation induced by a natural agonist ADP and carotid artery and mesenteric artery thrombosis. Tanipamox is used as a novel candidate drug for resisting formation of platelets and arterial thrombosis blocks in fundamental research of thrombotic diseases, and has potential application value in prevention and treatment of arterial thrombosis related diseases.